Martin mark - Xbrane Biopharma Chief Officer

XBRANE Stock

SEK 0.16 0.01 5.88%

Insider

Martin mark is Chief Officer of Xbrane Biopharma AB

Age	43
Phone	46 7 60 34 67 33
Web	https://www.xbrane.com

Xbrane Biopharma Management Efficiency

The company has return on total asset (ROA) of (0.1313) % which means that it has lost $0.1313 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3703) %, meaning that it generated substantial loss on money invested by shareholders. Xbrane Biopharma's management efficiency ratios could be used to measure how well Xbrane Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Xbrane Biopharma to Peers

Predict price of Xbrane Biopharma

Xbrane Biopharma AB has accumulated 36.48 M in total debt with debt to equity ratio (D/E) of 48.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Xbrane Biopharma has a current ratio of 1.42, which is within standard range for the sector. Debt can assist Xbrane Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Xbrane Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Xbrane Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Xbrane to invest in growth at high rates of return. When we think about Xbrane Biopharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	CarlJohan MD	Vicore Pharma Holding	67
	Klaus Sindahl	Hansa Biopharma AB	N/A
	Anita BCom	Saniona AB	55
	Mustafa Demirbker	XSpray Pharma AB	N/A
	Sren MSc	Hansa Biopharma AB	58
	Jessica Shull	Vicore Pharma Holding	N/A
	Grald Jesson	XSpray Pharma AB	N/A
	Palle MS	Saniona AB	65
	Per Andersson	XSpray Pharma AB	56
	Hans Jeppsson	Vicore Pharma Holding	N/A
	Anne Lanner	Hansa Biopharma AB	54
	Kicki Johansson	Vicore Pharma Holding	65
	Nina Carlen	Vicore Pharma Holding	N/A
	Rami Levin	Saniona AB	54
	AnnaKarin Ekberg	XSpray Pharma AB	57
	Katja Margell	Hansa Biopharma AB	N/A
	Emanuel Bjrne	Hansa Biopharma AB	50
	Charlotta Liljebris	XSpray Pharma AB	59
	Rohit Batta	Vicore Pharma Holding	N/A
	Jorgen Drejer	Saniona AB	68
	Johan Raud	Vicore Pharma Holding	N/A

Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people. Xbrane Biopharma AB (XBRANE) is traded on Stockholm Exchange in Sweden and employs 74 people.

Management Performance

	Return On Equity	-0.37
	Return On Asset	-0.13

Xbrane Biopharma Leadership Team

Elected by the shareholders, the Xbrane Biopharma's board of directors comprises two types of representatives: Xbrane Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xbrane. The board's role is to monitor Xbrane Biopharma's management team and ensure that shareholders' interests are well served. Xbrane Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xbrane Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Nina Ivers, Head HR
	Maria Edebrink, Head Assurance
	Siavash Bashiri, COO, Head of Biosimilars
	Dina Jurman, Head of Clinical Affairs
	Anette Lindqvist, CFO Relations
	Martin mark, Chief Officer
	David Vikstrm, Chief Officer
	Associate Gier, CoFounder
	Samuel Wagner, CoFounder Board
	Erik Domines, G Counsel

Xbrane Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xbrane Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.37
	Return On Asset	-0.13
	Operating Margin	(4.61) %
	Current Valuation	2.32 B
	Shares Outstanding	27.51 M
	Shares Owned By Insiders	35.23 %
	Shares Owned By Institutions	22.09 %
	Price To Earning	(10.92) X
	Price To Book	7.49 X
	Price To Sales	75.09 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Other Information on Investing in Xbrane Stock

Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC